Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.
Also called NCT03984760
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 240 participants
- Sponsor
- Registry
-
NCT03984760
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT03984760. Randomized; no masking; primary purpose treatment. Start 2019-06-19 (actual); primary completion 2021-02-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- Condition
- Hyperphosphatemia
- Condition
- End Stage Renal Disease
- Condition
- ESRD
- Intervention (Drug)
- Ferric Citrate
- Intervention (Drug)
- Sevelamer Carbonate
- Lead sponsor
- Panion & BF Biotech Inc.
- Collaborator
- Shandong Weigao Panion Pharmaceutical Co. Ltd.
Record details
- Record id
cardio:ct-nct03984760- Content hash
b3cdcb66c3fcd84a7ec29ca02e4c80a28f8435001bb6c94fe95212136a595978